India’s Shantha Biotech Draws Interest From MNCs And Universities Alike
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The race to buy an equity stake in India's vaccine maker Shantha Biotechnics is taking a curious turn with a few international academic institutions and universities showing interest in the company's product pipeline and marketed vaccines
You may also be interested in...
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
MUMBAI - In a takeover battle that lasted several months, drug maker Sanofi-Aventis emerged winner beating global rival GlaxoSmithKline among others to lap up a majority equity stake in India's Shantha Biotechnics from fellow French pharmaceutical firm Merieux Alliance. Shantha Biotechnics was valued at €550 million ($750 million) on expected sales of €90 million for the current financial year
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
MUMBAI - In a takeover battle that lasted several months, drug maker Sanofi-Aventis emerged winner beating global rival GlaxoSmithKline among others to lap up a majority equity stake in India's Shantha Biotechnics from fellow French pharmaceutical firm Merieux Alliance. Shantha Biotechnics was valued at €550 million ($750 million) on expected sales of €90 million for the current financial year
Seoul-based IVI Partners With Indian Shantha Biotechnics For Low-Cost Cholera Vaccine Licensed in India
SEOUL - A new oral cholera vaccine developed by Seoul-based International Vaccine Institute has been licensed to India's Shantha Biotechnics, paving the way for worldwide use of a low-cost cholera vaccine in developing countries, where most cholera cases occur, the IVI said